CRANBURY, N.J.--(BUSINESS WIRE)--CURE® magazine, the nation’s leading consumer digital and print media enterprise focused entirely on patients with cancer, honored Al Musella, D.P.M.; Linda Liau, M.D.; Kay Verble; and Matt Anthony as this year’s winners of its third annual Glioblastoma Multiforme (GBM) Heroes® Awards. The celebration gala took place yesterday at the City View at the Metreon in San Francisco during the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology.
“Each year, we are honored to award these heroes, who have made significant impact in the GBM community. We are proud of their contributions and are pleased to bring these heroes forward to be recognized for their hard work,” said Michael J. Hennessy Jr., president of Michael J. Hennessy Associates, Inc., parent company of CURE® magazine.
Guest speaker Maria Menounos presented an emotional keynote address during the gala. An actress, a writer and a TV host, Menounos has also been a New York Times bestselling author and CEO and co-founder of AfterBuzz TV, and she has delved into professional wrestling. Most important, Menounos is a brain tumor survivor and a caregiver for her mother, who is battling brain cancer.
The honorees of the 2017 GBM Heroes® Award were nominated by patients, healthcare professionals, advocates and peers for their dedication to the field of glioblastoma multiforme. The winners have excelled in providing care for patients, tremendously contributed to research and strongly advocated to advance the scientific research.
The CURE® magazine 2017 GBM Heroes® are:
Al Musella, D.P.M., Musella Foundation
Musella became involved in the GBM community after his sister-in-law and father were diagnosed with glioblastoma multiforme. To better connect the GBM community, he created an online database and support group. He also founded the Brain Tumor Virtual Trial and the Musella Foundation for Brain Tumor Research & Information Inc.
Linda M. Liau, M.D., Ph.D., MBA
Liau is a renowned, board-certified neurosurgeon, professor and chair of the department of neurosurgery at the David Geffen School of Medicine at UCLA. She specializes in intraoperative functional brain mapping and imaging for resection of brain tumors such as gliomas, meningiomas and metastatic tumors. Liau has written more than 150 peer-reviewed research articles and has been recognized as a Top Doctor by U.S. News & World Report, which places her among the top 1 percent in the nation in her specialty.
Kay Verble, executive director, the Sontag Foundation; the Brain
Verble is a longtime supporter of the GBM community. As executive director of the Sontag Foundation, she works closely with early-career researchers and clinicians who have received Sontag grants for brain cancer research, and she created a program of high-touch patient navigation services provided by a multidisciplinary team of nurses and social workers. Additionally, Verble serves as a key player in the success of a brain tumor support group in Northeast Florida.
Matt Anthony, Head for the Cure Foundation
In memory of his brother Chris, who passed away from GBM, Anthony and his family established the Head for the Cure Foundation in 2006. The foundation hosts 5k run/walks in 22 markets, which has raised over $9 million to support the work of the Brain Tumor Trials Collaborative (BTTC). In addition to his role at the Cure Foundation, Anthony also holds board positions with companies including VML Foundation, the BTTC and the MD Anderson Cancer Center Board of Visitors.
The GBM Heroes® Recognition program is sponsored by Novocure, a global oncology company.
CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc. family of businesses, which includes the acclaimed OncLive® (www.onclive.com) platform of resources for the practicing oncologist. For more information, visit curetoday.com or mjhassoc.com.
Novocure is a global oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. Headquartered in Jersey Isle, U.K., Novocure’s U.S. operations are based in Portsmouth, New Hampshire, and New York City. The company also has offices in Switzerland, Germany, and Japan, as well as a research center in Haifa, Israel.